Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

NCT07362017•Vanda Pharmaceuticals

Summary

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

•Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
•History of an allergic reaction or known and/or significant sensitivity to study drug

Key Dates

Start Date

January 1, 2026

Primary Completion Date

August 1, 2028

Completion Date

December 1, 2028

Last Updated

January 23, 2026

Enrollment

300

ESTIMATED participants

Conditions

Moderate-to-severe Chronic Plaque Psoriasis

Interventions

Ponesimod

DRUG

Contacts

Vanda Pharmaceuticals, Inc.

CONTACT